KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2026)

Amneal Pharmaceuticals has reported Net Income towards Common Stockholders over the past 8 years, most recently at $49.6 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 339.0% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $127.9 million, up 273.17%, while the annual FY2025 figure was $127.9 million, 209.45% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $49.6 million at Amneal Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $49.6 million in Q4 2025 and troughed at -$120.8 million in Q2 2022.
  • A 5-year average of -$7.5 million and a median of $2.3 million in 2021 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 460.06% in 2023 and fell as far as 2176.69% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$6.4 million in 2021, then skyrocketed by 32.05% to -$4.3 million in 2022, then tumbled by 2176.69% to -$98.6 million in 2023, then soared by 78.97% to -$20.7 million in 2024, then surged by 339.0% to $49.6 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for AMRX at $49.6 million in Q4 2025, $18.1 million in Q3 2025, and $35.6 million in Q2 2025.